Hypothesis

Senolytic drugs such as dasatinib+quercetin (D+Q) preferentially eliminate senescent cells whose mitochondrial ROS production exceeds a tissue‑specific threshold, thereby shifting the SASP from a pro‑survival to a pro‑apoptotic profile.

Mechanistic rationale

Recent work shows that senolytic efficacy in mice correlates with clearance of senescent oligodendrocyte progenitors and reversal of atherosclerosis [1, 2]. Human trials, however, reveal modest biomarker changes without clear functional benefit [3, 4]. One explanation is heterogeneity in the metabolic state of senescent cells across individuals and organs. We propose that senescent cells sustain a elevated mitochondrial ROS set‑point that drives NF‑κB‑dependent SASP expression. When ROS surpass a critical level, the antioxidant capacity is overwhelmed, leading to oxidative inhibition of BCL‑XL and MCL‑1, rendering the cells dependent on BCL‑2 family survival signals that dasatinib can disrupt. Conversely, cells with low mitochondrial ROS rely on alternative pathways (e.g., PI3K/AKT) and are resistant to D+Q.

Testable prediction

In humans, baseline mitochondrial ROS measured in circulating senescent CD4+ T cells (using MitoSOX flow cytometry) will positively correlate with the magnitude of senolytic‑induced reduction in plasma SASP factors (e.g., IL‑6, MMP‑9) after a single D+Q cycle. Furthermore, pharmacologically lowering mitochondrial ROS with a low dose of the mitochondria‑targeted antioxidant MitoQ will blunt this SASP reduction, whereas a mild mitochondrial complex III inhibitor (antimycin A at sub‑toxic dose) will enhance it.

Falsifiable experimental design

1. Recruit 60 participants with early‑stage diabetic kidney disease (the cohort used in the D+Q DKD trial) [3].
2. Before treatment, isolate peripheral blood mononuclear cells, stain for senescence markers (p16^INK4a^+, p21^Cip1^+, MitoSOX) and quantify mitochondrial ROS intensity by flow cytometry.
3. Administer a standard D+Q regimen (dasatinib 100 mg + quercetin 1000 mg) for three consecutive days.
4. Collect plasma 48 h post‑dose and measure IL‑6, MMP‑9, and VEGF‑A by ELISA.
5. In a randomized, double‑blind crossover sub‑study (n = 30), give MitoQ 10 mg daily or placebo for 7 days prior to D+Q; repeat SASP measurement.
6. Perform statistical analysis: (a) Spearman correlation between baseline mitochondrial ROS and % change in each SASP factor; (b) interaction test comparing MitoQ vs placebo on the ROS‑SASP slope. Falsification: If no significant correlation is observed (p > 0.05) and MitoQ does not alter the SASP response, the hypothesis is refuted.

Implications

A positive result would justify enrichment strategies for senolytic trials based on a functional senescence assay, addressing the biomarker gap highlighted in the preclinical‑to‑clinical translation discussion [5, 6]. It would also reveal a mechanistic link between mitochondrial metabolism and senolytic susceptibility, opening avenues to combine mild mitochondrial modulators with existing senolytics to broaden efficacy across heterogeneous tissues.